Cambridge Investment Research Advisors Inc. raised its holdings in shares of Teladoc Health, Inc. (NYSE:TDOC – Get Rating) by 25.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 31,031 shares of the health services provider's stock after purchasing an additional 6,242 shares during the period. Cambridge Investment Research Advisors Inc.'s holdings in Teladoc Health were worth $1,031,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Kinnevik AB publ acquired a new stake in shares of Teladoc Health in the 4th quarter valued at approximately $458,235,000. ARK Investment Management LLC raised its position in shares of Teladoc Health by 2.9% in the 1st quarter. ARK Investment Management LLC now owns 19,466,931 shares of the health services provider's stock valued at $1,404,150,000 after acquiring an additional 544,733 shares during the period. Greenhaven Road Investment Management L.P. acquired a new stake in shares of Teladoc Health in the 4th quarter valued at approximately $27,546,000. Marshall Wace LLP raised its position in shares of Teladoc Health by 70.2% in the 4th quarter. Marshall Wace LLP now owns 438,030 shares of the health services provider's stock valued at $40,219,000 after acquiring an additional 180,654 shares during the period. Finally, Worldquant Millennium Advisors LLC acquired a new stake in shares of Teladoc Health in the 1st quarter valued at approximately $11,437,000. 92.46% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently weighed in on TDOC. Needham & Company LLC downgraded shares of Teladoc Health from a "buy" rating to a "hold" rating in a research report on Thursday, July 28th. Barclays lowered their target price on Teladoc Health from $45.00 to $42.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 20th. StockNews.com raised Teladoc Health to a "sell" rating in a research note on Tuesday, August 9th. Oppenheimer lowered their target price on Teladoc Health from $65.00 to $55.00 and set an "outperform" rating for the company in a research note on Thursday, July 28th. Finally, The Goldman Sachs Group cut Teladoc Health from a "buy" rating to a "neutral" rating and lowered their target price for the stock from $55.00 to $36.00 in a research note on Thursday, July 28th. Two investment analysts have rated the stock with a sell rating, twenty-four have assigned a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, Teladoc Health presently has an average rating of "Hold" and a consensus price target of $64.13.

Teladoc Health Stock Up 8.2 %

Teladoc Health (NYSE:TDOC – Get Rating) last announced its quarterly earnings results on Wednesday, July 27th. The health services provider reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($0.71) by $0.27. Teladoc Health had a negative net margin of 441.94% and a negative return on equity of 2.04%. The business had revenue of $592.38 million for the quarter, compared to analyst estimates of $586.86 million. On average, analysts forecast that Teladoc Health, Inc. will post -1.54 earnings per share for the current year.

Insider Buying and Selling at Teladoc Health

In other Teladoc Health news, insider Arnnon Geshuri sold 4,098 shares of the business's stock in a transaction dated Friday, August 26th. The shares were sold at an average price of $34.27, for a total value of $140,438.46. Following the completion of the sale, the insider now owns 76,182 shares of the company's stock, valued at approximately $2,610,757.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, SVP Daniel Trencher sold 1,000 shares of the company's stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $30.18, for a total transaction of $30,180.00. Following the completion of the sale, the senior vice president now owns 25,408 shares of the company's stock, valued at approximately $766,813.44. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Arnnon Geshuri sold 4,098 shares of the company's stock in a transaction that occurred on Friday, August 26th. The stock was sold at an average price of $34.27, for a total transaction of $140,438.46. Following the sale, the insider now directly owns 76,182 shares of the company's stock, valued at approximately $2,610,757.14. The disclosure for this sale can be found here. Insiders sold 7,318 shares of company stock valued at $255,321 in the last quarter. Company insiders own 1.55% of the company's stock.

About Teladoc Health

(Get Rating)

Teladoc Health, Inc provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions.

Featured Stories

• Get a free copy of the StockNews.com research report on Teladoc Health (TDOC)
• Don't Give Up on These Q3 Losers
• The Anatomy of a Great Pension Plan
• 3 Safe Earnings Plays for a Risk-Off Market
• Tyson Foods Takes a Lickin' and Keeps on Tickin' Lower
• Small-Cap Catalyst Pharma Is Among Market's Best Price Performers

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.